Yujiro Hata, Ideaya Biosciences CEO
July 8, 2024 07:29 AM EDTUpdated 08:59 AM
R&D

Ideaya show­cas­es proof-of-con­cept da­ta in a boost to syn­thet­ic lethal­i­ty play

Amber Tong

Fresh Phase 2 da­ta are adding weight to Ideaya Bio­sciences’ case for a tar­get­ed ther­a­py it be­lieves could be a first-in-class treat­ment op­tion for cer­tain …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times